COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS

被引：0
|
作者：
Sabater, E. [1 ]
Rueda, A. [2 ]
Salar, A. [3 ]
Lopez-Guillermo, A. [4 ]
Oyagueez, I. [1 ]
Collar, J. M. [5 ]
机构：
[1] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[2] Hosp Costa del Sol, Dept Oncol, Marbella, Spain
[3] Hosp del Mar, Hematol Dept, Madrid, Spain
[4] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[5] Mundipharma Pharmaceut, Dept Med, Madrid, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1270
引用
收藏
页码：487 / 488
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [2] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [3] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [4] Rituximab-Bendamustine in First Line Treatment of Patients with Follicular Lymphoma. Results of Prospective Multicenter Study
    Ekaterina, Nesterova
    Kravchenko, Sergey K.
    Kovrigina, Alla M.
    Plastinina, Lubov V.
    Mangasarova, Yana K.
    Gorenkova, Liliya
    Vorobyev, Vladimir
    Mariin, Dmitriy
    Baryakh, Elena A.
    Polyakov, Yuriy
    Zeynalova, Pervin
    Volodicheva, Elena
    Glonina, Nataliya
    Savchenko, Valeriy G.
    BLOOD, 2017, 130
  • [5] Cost-effectiveness of rituximab plus CVP for first-line treatment of advanced indolent lymphoma
    Hornberger, J.
    Reyes, C.
    Verhulst, E.
    Lubeck, D.
    Valente, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
  • [7] A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma.
    Zinzani, PL
    BLOOD, 2001, 98 (11) : 842A - 842A
  • [8] RITUXIMAB-BENDAMUSTINE AS FIRST LINE OF TREATMENT IN PATIENTS WITH FOLLICULAR LYMPHOMA. EXPERIENCE OF ONE CENTER
    Melian Haridian, De la Nuez
    Henriquez Hugo, Luzardo
    Cabrera Alexia, Suarez
    Gonzalez Paula, Fernandez-Caldas
    Cruz Naylen, Cruz
    Borrego Asuncion, Borrero
    Juan Francisco, Lopez Rodriguez
    Curbelo Alejandro, Morales
    De La Cruz Marcos, Cabezas
    Maria Teresa, Gomez Casares
    HAEMATOLOGICA, 2021, 106 (10) : 296 - 297
  • [9] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [10] FIRST LINE TREATMENT WITH BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Buenasmananas Cervantes, D.
    Calle Primo, C.
    Nebro Luque, M. dM
    Hernandez Ruiz, B.
    HAEMATOLOGICA, 2015, 100 : 266 - 266
12345